Article

Macusight's lead product has positive phase 1 results

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

Union City, CA-MacuSight's lead product candidate, sirolimus, for patients with chronic, clinically significant diabetic macular edemahas shown positive initial results in its phase 1 study.

These findings were presented at the 40th annual meeting of the Retina Society by Mark Blumenkranz, MD, chairmen of MacuSight's scientific advisory board and professor and chairman of the department of ophthalmology, Stanford University School of Medicine.

The study was randomized, open-label and investigators analyzed the safety, tolerability, and biological activity of sirolimus when delivered by either subconjunctival or intravitreal injection.

Subconjunctival injections, which are less invasive and more convenient, were used instead of the intravitreal injections, which sometimes caused patient discomfort and a risk of serious infection in some patients.

Patients who received the subconjunctival injection had mean improvements in visual acuity of 8.5 and 7.4 letters over baseline, using the standard ETDRS eye chart. Foveal thickness also decreased.

There was no sign of increased IOP or inflammatory response, and MacuSight intends to complete its collection and analysis of all data from this trial and present final findings next year.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.